12 Mo. Price Change : 68% - CVD has outperformed the S&P 500 by 42%

Get Trend Analysis Icon Get Trend Analysis

Partner Headlines

  1. UPDATE: ISI Group Reiterates Neutral Rating, Raises PT on Covance

    Benzinga
  2. UPDATE: Jefferies Reiterates Hold Rating, Raises PT on Covance

    Benzinga
  3. UPDATE: J.P. Morgan Reiterates Overweight Rating, Raises PT on Covance

    Benzinga
  4. UPDATE: Sterne Agee Reiterates Buy Rating, Raises PT on Covance

    Benzinga
  5. Top Narrow Based Indexes For January 14, 2013

    Benzinga
  6. Four European Stocks Worth a Look Now (DLPH, ICLR, IR, LYB)

    Benzinga
  7. Covance, Inc. (CVD) Chairman and CEO Joseph L Herring sells 40,800 ...

    GuruFocus
  8. Top 4 Mid-Cap Stocks In The Medical Laboratories & Research ...

    Benzinga
  9. Top 4 Mid-Cap Stocks In The Medical Laboratories & Research ...

    Benzinga
  10. Covance Inc. Reports Operating Results (10-K)

    at GuruFocus
  11. Stocks Fall As Greek Talks Hit Another Bump With CF Industries ...

    At Market Intelligence Center
  12. UPDATE: Citigroup Downgrades Covance to Neutral

    at Benzinga
  13. Stocks Give Back Early Gains With Hess (HES) and Toll Brothers ...

    At Market Intelligence Center
  14. UPDATE: Goldman Sachs Downgrades Covance to Neutral

    at Benzinga
  15. Goldman Sachs Downgrades Covance to Neutral

    at Benzinga
  16. Covance Board Authorizes $300M Stock Buyback

    at Benzinga
  17. Biotechs, HMOs, Digital Records Push Aid Health Stocks

    at IBD
  18. UPDATE: Citigroup Maintains Buy, Lowers PT to $55 on Covance

    at Benzinga
  19. Stocks Mixed at Midday with Research in Motion (RIMM) and Walgreen ...

    At Market Intelligence Center
  20. Jefferies Lowers PT on Covance to $44

    at Benzinga
  21. Covance Reiterates Full Year 2011 Revenue and Pro Forma EPS

    at Benzinga
People viewing CVD also viewed: , , , , , ,
Marketplace
Trading Center